What is NAD+?

NAD+ is a cellular redox coenzyme involved in energy metabolism and enzyme signaling. Direct NAD+ products are chemically distinct from NMN and nicotinamide riboside. [1][14][15]

Direct NAD+ injectable, nasal, and topical preparations are compounded products rather than FDA-approved drug presentations. Their exact concentration and pharmacy instructions control the calculation. [1][14][15]

What NAD+ is investigated for

NAD+ evidence is grouped by practical use case and injectable, nasal, and topical route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

Cardiac function

Injectable

56% Emerging

This is a limited human signal for one IV clinical context, not evidence for subcutaneous, nasal, topical, or general anti-aging use. [2][4]

Human evidence

A randomized placebo-controlled trial in 180 adults with heart failure from ischemic cardiomyopathy reported improved left-ventricular ejection fraction at one month after a short intravenous course. It was single-center, used IV delivery, and did not establish broader clinical-event or wellness benefits. [2][4]

Animal / mechanistic evidence

Mechanistic and preclinical NAD+ literature supports cardiovascular plausibility but cannot replicate the human clinical result. [10][13]

Olfactory recovery

Nasal

28% Limited

The evidence is preclinical and cannot establish effectiveness or a human treatment timeline. [15]

Human evidence

No controlled human intranasal outcome trial was identified for olfactory recovery. [4][15]

Animal / mechanistic evidence

Cultured human olfactory stem cells and a mouse anosmia model showed biological and functional signals after intranasal NAD+. [15]

Energy or fatigue support

Injectable, Nasal, Topical

16% Insufficient

Energy and fatigue benefits remain unproven for the reviewed compounded routes. [3][4]

Human evidence

Systematic reviews found no eligible controlled direct IV or IM NAD+ outcome trials supporting common anti-aging or wellness claims through the reviewed search windows. [3][4]

Animal / mechanistic evidence

NAD+ is essential to energy metabolism, but biochemical necessity is not evidence that direct administration improves fatigue. [10][12]

Healthy aging and longevity

Injectable, Nasal, Topical

14% Insufficient

Healthy-aging claims are mechanistically plausible but clinically unestablished for direct NAD+. [4][7]

Human evidence

No human trial has shown that direct NAD+ extends lifespan or prevents age-related disease. Human blood NAD+ findings also vary by tissue and measurement approach. [6][4][7]

Animal / mechanistic evidence

Reviews describe age-related NAD+ biology and extensive preclinical rationale, mostly involving pathway manipulation or precursors rather than these direct compounded routes. [13][5][8]

Evidence snapshot

Overall confidence

Preliminary

40%

Direct NAD+ has documented compounded forms and limited human research, but no established route-matched wellness treatment standard. [1][14][15]

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

38%

Human evidence

Preliminary

Small infusion and experimental injection studies provide early human context. [1][14]

28%

Animal / preclinical

Limited

Intranasal NAD+ evidence includes cell and mouse-model work rather than human nasal outcomes. [15]

55%

Mechanism support

Emerging

NAD+ is a central cofactor, but direct administration does not automatically establish tissue delivery or durable clinical benefit. [1][14][15]

Forms & administration

Direct NAD+ exposes three exact compounded presentations: a lyophilized vial mixed with bacteriostatic water, a metered nasal spray, and a metered topical cream. It does not reuse NMN or NR doses.

InjectableNasal sprayTopical

Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

Typical Range

Common protocol doses are 50 mg by injection, 30 mg intranasally, and 100 mg topically per application.

Frequency

Injections are scheduled 3 times weekly. Intranasal and topical products are used once daily.

Timing Considerations

Morning is the default timing for all three routes.

Cycle Length

The injectable cycle runs 30 days. Intranasal and topical schedules are ongoing.

What to expect

First hours (intravenous research only)

A small IV pilot showed rapid plasma and urine metabolite changes during a six-hour infusion; this describes handling of NAD+, not a proven symptom response. [1]

One month (cardiac trial only)

The ischemic-cardiomyopathy trial assessed cardiac function at one month; this timing should not be generalized to wellness or other routes. [2][4]

After stopping

Durability of any clinical effect after direct NAD+ stops has not been defined for these compounded routes. [3][4]

Safety profile

Direct NAD+ has limited route-matched human safety data. Product quality is a material risk for sterile injectables because FDA has documented serious reactions linked to excessive endotoxin in compounded NAD+ products. [16][17][18]

Cautions

Sterile injectable product quality [16][17]
Urgent reaction symptoms [16][17]

What we don't know

A reliable common-adverse-effect rate, long-term safety profile, and equivalence across formulations have not been established. [3][4][16]

Who NAD+ is not for

Route-specific avoid and medical-review notes:

Pregnancy or breastfeeding without clinician review
Pregnancy and breastfeeding safety data are insufficient for direct injectable, nasal, or topical NAD+ use. [3][4]

Pairing notes

Commonly included in these stacks

NAD+ / MOTS-c / 5-Amino-1MQ

NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism.

NAD+MOTS-c5-Amino-1MQ

Related peptides

NMN Nicotinamide Riboside (NR)

Regulatory status

United States

NAD+ is not FDA-approved as a drug for the reviewed routes. Compounded, supplement, and research-market availability are separate from FDA approval. [16][17][18]

Route	FDA drug approval	503A compounding
Injectable	Not Approved NAD+ is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]	Not Listed NAD+ does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]
Nasal	Not Approved NAD+ is not FDA-approved as a nasal drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]	Not Listed NAD+ does not have FDA-approved nasal dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]
Topical	Not Approved NAD+ is not FDA-approved as a topical drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]	Not Listed NAD+ does not have FDA-approved topical dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]

Injectable

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a injectable drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]

503A compounding

Not Listed

NAD+ does not have FDA-approved injectable dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]

Nasal

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a nasal drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]

503A compounding

Not Listed

NAD+ does not have FDA-approved nasal dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]

Topical

FDA drug approval

Not Approved

NAD+ is not FDA-approved as a topical drug for the reviewed use. Compounded, supplement, or research availability is separate from FDA approval. [16][17][18]

503A compounding

Not Listed

NAD+ does not have FDA-approved topical dosing for the reviewed use; any compounded preparation remains product- and prescriber-specific. [16][17][18]

International

Product-specific status must be checked in each national medicines or supplement register.

Sports & competition

Tested athletes should obtain sport-specific review for non-approved NAD-pathway products. [20]

How it works

NAD+ links glycolysis, the citric-acid cycle, and oxidative phosphorylation by accepting and transferring electrons. This biochemical role is established, but it does not determine how much direct compounded NAD+ reaches each tissue. [1][14][15]

Injectable, nasal, and topical formulations create different exposure conditions. Route and formulation therefore matter when interpreting direct NAD+ research and product claims. [1][14][15]

Research gaps & open questions

What the current literature has not yet settled about NAD+:

Controlled human trials need to test direct subcutaneous, nasal, and topical NAD+ separately. [1][14][15]

Human studies should establish how much direct NAD+ or its metabolites reach target tissues after injection, nasal use, or topical use. [1][14][15]

Long-term safety and product-quality surveillance remain necessary for compounded injectable products. [1][14][15]

Independent replication is needed for the one-month cardiac-function signal, with clinical-event outcomes and longer follow-up. [2][4]

Human research should determine which tissue-specific NAD+ measures are clinically meaningful rather than treating whole-blood NAD+ as a universal aging biomarker. [6][7]

Common questions

Is NAD+ the same as NMN or NR?

No. NAD+ is the coenzyme itself; NMN and nicotinamide riboside are different precursor molecules and have separate records. [1][14][15]

Does the selected NAD+ vial need bacteriostatic water?

Yes. The selected preset uses one 1,000 mg lyophilized NAD+ vial with exactly 5 mL bacteriostatic water, producing 200 mg/mL. A 50 mg dose is 0.25 mL or 25 U on a U-100 syringe.

Does direct NAD+ reliably improve energy or fatigue?

That has not been established. Reviews found the direct human outcome literature too sparse to support common wellness claims, even though NAD+ is essential to cellular energy metabolism. [3][4]

Has direct NAD+ been shown to slow aging or extend lifespan?

No human lifespan or disease-prevention benefit has been demonstrated. Aging-pathway research provides rationale, not proof of a clinical anti-aging effect. [5][4][7]

Can IV, subcutaneous, nasal, and topical NAD+ evidence be combined?

No. Each route creates different exposure and product-quality considerations, so findings should remain route-specific. [1][14][15]

Myths & misconceptions

Myth

All NAD+, NMN, and NR products use the same dose.

Reality

They are different molecules and presentations; their doses, routes, and preparation instructions are not interchangeable. [1][14][15]

Myth

A whole-blood NAD+ result is a validated biological-aging clock.

Reality

Human findings differ by tissue and assay, and a 2026 study found whole-blood NAD+ did not vary with age or lifestyle intervention; it is not a validated standalone aging clock. [6][7]

Myth

Every compounded NAD+ injectable has the same safety profile.

Reality

Sterility and endotoxin control matter. FDA has documented serious reactions tied to contaminated compounded NAD+ injectables. [16][17]

History & discovery

NAD+ moved from a foundational metabolic coenzyme to a proposed therapeutic target as researchers mapped its roles in redox chemistry, signaling, and age-related biology. Modern interest in direct administration should be separated from the much larger human literature on oral precursors such as NR and NMN. [10][12][11][4]

Early fermentation research identified the coenzyme activity later understood as NAD chemistry. [10][12]

A small pilot characterized plasma and urine metabolites during a six-hour intravenous NAD+ infusion. [1]

A cardiac trial and a systematic review added human context while underscoring the lack of controlled evidence for common anti-aging and wellness use. [2][4]

Published research 17 studies

[1]

A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD

Frontiers in Aging Neuroscience, 2019-09-12. human clinical.

[2]

Effect of Nicotinamide Adenine Dinucleotide on Heart Failure Caused by Ischemic Cardiomyopathy: A Randomized, Placebo-Controlled Trial

American Journal of Cardiovascular Drugs, 2026. human clinical.

[3]

Evaluation of safety and effectiveness of NAD in different clinical conditions: a systematic review

American Journal of Physiology - Endocrinology and Metabolism, 2024. review.

[4]

NAD+ supplementation for anti-aging and wellness: A PRISMA-guided systematic review of preclinical and clinical evidence

Ageing Research Reviews, 2026. review.

[5]

Age-related NAD+ decline

Experimental Gerontology, 2020. review.

[6]

Age-associated changes in oxidative stress and NAD+ metabolism in human tissue

PLOS ONE, 2012. human clinical.

[7]

Human whole-blood NAD+ levels do not vary with age or lifestyle interventions

Nature Metabolism, 2026. human clinical.

[8]

NAD+ as a central metabolic hub regulating the hallmarks of aging: Mechanisms and therapeutic implications

Mechanisms of Ageing and Development, 2026. review.

[9]

The differential impact of three different NAD+ boosters on circulatory NAD and microbial metabolism in humans

Nature Metabolism, 2026. human clinical.

[10]

NAD+ metabolism in health and disease

Trends in Biochemical Sciences, 2007. review.

[11]

NAD+ Intermediates: The Biology and Therapeutic Potential of NMN and NR

Cell Metabolism, 2018. review.

[12]

The human NAD metabolome: Functions, metabolism and compartmentalization

Critical Reviews in Biochemistry and Molecular Biology, 2015. review.

[13]

NAD and the aging process: Role in life, death and everything in between

Molecular and Cellular Endocrinology, 2017. review.

[14]

Absorption and Tolerability of Injectable Administration of Niagen+, as Compared to NAD+

ClinicalTrials.gov. clinical trial registry.

[15]

Therapeutic effect of intranasal nicotinamide adenine dinucleotide in the restoration of olfactory dysfunction

Experimental & Molecular Medicine, 2026-07-01. animal.

[16]

FDA reminds compounders to use ingredients suitable for sterile compounding

U.S. Food and Drug Administration, 2024. regulatory.

[17]

GenoGenix LLC Warning Letter

U.S. Food and Drug Administration, 2026-01-20. regulatory.